Format

Send to

Choose Destination
Curr Opin Chem Biol. 2008 Feb;12(1):11-7. doi: 10.1016/j.cbpa.2008.01.019. Epub 2008 Mar 7.

The Sirtuin family: therapeutic targets to treat diseases of aging.

Author information

1
Sirtris Pharmaceuticals, Inc., 790 Memorial Drive, Cambridge, MA 02139, USA. jmilne@sirtrispharma.com

Abstract

Sirtuins have emerged as therapeutic targets to treat age-related diseases. There are seven human Sirtuins (SIRT1-7) that display diversity in cellular localization and function. Growing evidence suggests that small-molecule activators of SIRT1 may counteract age-related afflictions such as type 2 diabetes. Alternatively, inhibitors of SIRT2 may be useful in the treatment of neurodegenerative diseases such as Parkinson's disease. Recent discoveries of small-molecule and protein modulators of Sirtuin deacetylation activity have provided enormous insight into the biological and molecular functions of Sirtuins and have validated their potential as therapeutics.

PMID:
18282481
DOI:
10.1016/j.cbpa.2008.01.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center